石藥集團(01093.HK)首季基本純利升10.3%至15.37億元 恩必普及抗腫瘤產品維持穩定增長
格隆匯5月25日丨石藥集團(01093.HK)公佈,截至2022年3月31日止3個月,集團實現收入總額78.74億元人民幣(單位下同),同比增長16.9%;股東應占基本溢利為15.37億元,同比增長10.3%;股東應占溢利為14.05億元,每股基本盈利為11.79分。
成藥業務
於2022年第一季度,成藥業務錄得銷售收入63.02億元,同比增加15.0%。期內,恩必普及抗腫瘤產品維持穩定增長,而近年新上市產品的貢獻持續上升。此外,新獲批創新藥多恩達(鹽酸米託蒽醌脂質體注射液)於2月成功上市。
原料產品業務
於2022年第一季度,維生素C產品錄得銷售收入7.00億元,同比增加33.7%。受惠於生產能力的提升,期內維生素C產品的生產量及銷售量均進一步增加,但產品價格則有所下調。抗生素及其它產品的銷售收入亦增加14.7%至4.46億元,這主要是因為個別抗生素產品銷售量提高所致。
功能食品及其它業務
主要因為咖啡因產品銷售量及價格上升的拉動,該業務於期內的銷售收入同比增加24.8%至4.25億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.